Business Wire

IFF Recognizes Anne Flipo with Master Perfumer Designation

8.2.2019 00:15:00 EET | Business Wire | Press release

Share

Regulatory News:

International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), named Anne Flipo Master Perfumer, where she joins the ranks of the world’s finest scent artists. The Company’s designation recognizes perfumers who have demonstrated consistent and outstanding levels of creativity and craftsmanship in the art of perfumery, and exceptional leadership in and measurable impact on the industry. Ms. Flipo is the fifth perfumer at IFF recognized with the prestigious title, which was established in 2013.

“One of the great distinctions about IFF is the sheer quality and extraordinary talent of our people,” said Andreas Fibig, IFF Chairman & CEO. “Our perfumers create fragrances that form the sensory backdrop to people’s lives – something Anne understands well. I am thrilled at her recognition, not only for her lifetime of achievements thus far, but for the great things we continue to expect from her.”

Raised in Picardy, France, Ms. Flipo’s childhood was scented with wildflowers and vegetable gardens. She was fascinated by nature, cooking, and music, influences which remain with her today. After her baccalaureate, she joined ISIPCA, the legendary school for perfume, flavors, and cosmetics, to begin her training for a career in flavors. While an apprentice, she encountered essential oils for perfumery and realized that a life in fragrances is where her future would be made. Once ensconced in the industry, Ms. Flipo worked alongside some of the greats in the profession, each of whom left their influence on the young perfumer. She honed her personal style and approach and as she did, enjoyed a series of successes that established her as a perfumer to watch. Since joining IFF in 2004, her list of “wins” with extraordinary and iconic brands has only grown.

Ms. Flipo said, “I would like to speak about my 15 years with IFF. The life of a perfumer can be challenging, but IFF gave me the room to come into my own skin. It forced me to be the master of my own life, to let go of the fear, to embrace who I am, and discover independence.” Ms. Flipo continued, “IFF supports you when you challenge yourself, and it treats us as individuals, rather than a machine. At IFF, you are part of a team, where I know I belong, and where I know that what I bring is unique and valued. I was able to overcome any obstacles thanks to the outstanding human fabric of the company, which holds everything together, and creates common values which we all stand for: passion, simplicity and kindness… and a bit of madness too!”

Ms. Flipo industry recognitions include the Cosmetique Magazine Perfumer of the Year award in 2014 and Cosmetic Executive Women (CEW) France Achiever Award for Creation in 2016. In addition, many of her fragrance creations have been the recipients of the Fragrance Foundation Awards in both the US and Europe.

“Anne’s admirers are countless,” said Nicolas Mirzayantz, Divisional CEO of Scent. “including her contemporaries, mentees, clients and endless consumers. Every one of her fragrance designs is a vivid combination of her passionate heart and curious, creative mind.” Mr. Mirzayantz continued, “Like her fellow Master Perfumers, Anne is committed to mentoring the next generation of perfumers as they take their exciting and distinct journeys. Their genuine appreciation of her vast knowledge, inspiring spirit and dynamic instruction supports their dreams to connect to the world through scent. I am truly thrilled to recognize Anne with this well-deserved honor.”

# # #

Meet IFF

International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) is a leading innovator of scent, taste, and nutrition, with over 110 manufacturing facilities, 100 R&D centers, and 33,000 customers globally. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumers experience in more than 150,000 unique products sold annually. Our 13,000 team members globally take advantage of leading consumer insights, naturals exploration, research and development, creative expertise, and customer intimacy to develop differentiated offerings for consumer products.

Learn more at www.iff.com, Twitter , Facebook, Instagram, and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Michael DeVeau
Head of Investor Relations and Communications & Divisional CFO, Scent
212.708.7164
Michael.DeVeau@iff.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough7.7.2026 16:00:00 EEST | Press release

Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in accelerating drug development timelines. Building on proven results in clinical reporting, where the collaboration has achieved up to first-draft clinical study reports (CSRs), the teams have now successfully applied similar AI capabilities to nonclinical data through high-quality parsing of raw and SEND datasets in a proof-of-concept. This advancement aligns with the Altasciences Acceleration Platform, designed to fast-track drug development across the early-phase development continuum. “This milestone reflects the power of in

Gurobi Launches Intelligence Hub to Deliver AI-Guided Workflows Across the Optimization Lifecycle7.7.2026 16:00:00 EEST | Press release

Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the launch of the Gurobi Intelligence Hub, the new home for Gurobi’s AI-powered optimization agents. The Intelligence Hub is designed to help users build, understand, troubleshoot, and interact with optimization models more effectively. Together, the Hub’s specialized agents leverage generative AI to guide users through workflows across the optimization lifecycle, creating new opportunities to make optimization more accessible, intuitive, and valuable for a broader range of users. The Modeler combines guided workflows with Gurobi’s optimization expertise to help users move from business problem to production-quality optimization model. Through an iterative process that helps refine requirements, validate assumptions, and develop acceptance tests, the Modeler gives users confidence that their model accurately reflects the intended business problem.The Explainer helps users interpret model instances

SS&C Expands Tokenized Investment Capabilities with Digital Cash Settlement7.7.2026 16:00:00 EEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced plans to enable digital cash settlement for tokenized investment transactions using regulated forms of digital cash, including stablecoins and tokenized commercial bank deposits. The announcement builds on the successful launch of SS&C's live tokenized fund issuance and distribution capabilities earlier this year following the acquisition of Calastone in 2025. SS&C already enables asset managers to bring tokenized versions of traditional investment funds to market through the infrastructure and connectivity they already use, helping bridge traditional and digital investment markets. As interest in tokenized investment products continues to grow, the market is increasingly looking beyond tokenization towards the infrastructure needed to support digital transactions. Having already enabled the issuance and distribution of tokenized funds, SS&C is now extending its innovation roadmap to support the next stage of the digital i

Quaise Energy Raises $134 Million in Initial Close of Series B to Build World’s First Superhot Geothermal Power Plant7.7.2026 15:01:00 EEST | Press release

Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced the first close of its Series B financing, raising $134 million with additional equity and debt capital expected to close imminently. The round was led by Prelude Ventures, with strategic investments from JERA and Idemitsu, two of Japan's largest energy companies. Nearly all existing investors, including Safar Partners, participated in the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707844187/en/ The proceeds from Series B will fund Project Obsidian, the world’s first commercial superhot geothermal power plant, and the continued development and commercialization of Quaise's millimeter wave drilling system towards depths in excess of 5 km. Project-level equity and debt financing is concurrently being raised as the company advances toward first revenues secured by yet-undisclosed commercial off-take partners. The Series

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development7.7.2026 15:00:00 EEST | Press release

Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk of light-chain mispairing and providing a robust molecular foundation for subsequent BsADC development. By bringing together the complementary capabilities of Biocytogen and Whitehawk, the collaboration aims to identify BsADC candidates with differentiated targeting profiles and therapeutic potential. “W

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye